{
    "organizations": [],
    "uuid": "f309a06b2136e7ce9b392de75c730634086e2773",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-anaptysbio-qtrly-loss-per-share-06/brief-anaptysbio-qtrly-loss-per-share-0-63-idUSASC0A0PJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Anaptysbio Qtrly Loss Per Share $0.63",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - AnaptysBio Inc:\n* ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES\n* ANAPTYSBIO INC - TOP-LINE PHASE 2A DATA FROM ANB020 IN EOSINOPHILIC ASTHMA EXPECTED IN Q3 OF 2018\n* ANAPTYSBIO INC - EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019\n* ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.63 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T05:50:00.000+03:00",
    "crawled": "2018-05-09T12:30:54.042+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "anaptysbio",
        "inc",
        "anaptysbio",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "pipeline",
        "update",
        "anaptysbio",
        "inc",
        "phase",
        "2a",
        "data",
        "anb020",
        "eosinophilic",
        "asthma",
        "expected",
        "q3",
        "anaptysbio",
        "inc",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "fund",
        "current",
        "operating",
        "plan",
        "end",
        "anaptysbio",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}